← Leaderboards
Lahouaria Hadri
Icahn School Of Medicine At Mount Sinai
$8,134,686
Attributed
$8,134,686
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.1M · FY2010–25$2.5M$1.9M$1.3M$625K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,134,686 · 6
By mechanism
R01$7,291,361 · 4
K01$674,325 · 1
R03$169,000 · 1
Top collaborators
No co-investigators on record.
Most similar at Icahn School Of Medicine At Mount Sinai
Same institution · by research overlap
- Yassine Sassi$2,618,723
- Gregg W. Stone$348,111
Others in their field
Top investigators on “Overexpression”
- Andrzej Joachimiak Joachimiak · University Of Chicago$32,767,365
- Benjamin L Handen · University Of Pittsburgh At Pittsburgh$24,209,146
- C Kent Osborne · Baylor College Of Medicine$23,157,545
- Norbert Perrimon · Harvard Medical School$23,056,106
- Philipp E Scherer · Ut Southwestern Medical Center$21,324,642
- Susan E Celniker · University Of Calif-Lawrenc Berkeley Lab$20,387,203
Research focus
OverexpressionPathway InteractionsIn VitroPhenotypeCell GrowthProteinsCellsLungSmooth Muscle MyocytesSamplingVascular RemodelingPathogenesisMessenger RnaKnockout MiceMolecularMigrationAdenovirusesRattusAffectHomeostasisPlayGrowthPathologicChronic
Grant awards (20)
The Chromatin Remodeling Factor ARID1a and the Epigenetic Landscape In Pulmonary Arterial Hypertension$839,217
R01 · FY2025 · HL · contact PI
Role of Epigenetic Regulator SIN3a in Pulmonary Endothelial Cells$838,703
R01 · FY2025 · HL · contact PI
Role of Epac1 in the Pathogenesis of Pulmonary Fibrosis$422,500
R01 · FY2025 · HL · contact PI
The Chromatin Remodeling Factor ARID1a and the Epigenetic Landscape In Pulmonary Arterial Hypertension$838,852
R01 · FY2024 · HL · contact PI
Role of Epigenetic Regulator SIN3a in Pulmonary Endothelial Cells$814,462
R01 · FY2024 · HL · contact PI
Role of Epac1 in the Pathogenesis of Pulmonary Fibrosis$422,500
R01 · FY2024 · HL · contact PI
Role of Epac1 in the Pathogenesis of Pulmonary Fibrosis$422,500
R01 · FY2023 · HL · contact PI
ARID1a and Chromatin Landscape in Pulmonary Vascular Disease$169,000
R03 · FY2023 · TR · contact PI
Role of Epac1 in the Pathogenesis of Pulmonary Fibrosis$422,500
R01 · FY2022 · HL · contact PI
Interactions of SERCA2a and BMPRII in Vascular Disease$423,750
R01 · FY2020 · HL · contact PI
Interactions of SERCA2a and BMPRII in Vascular Disease$476,681
R01 · FY2019 · HL · contact PI
Interactions of SERCA2a and BMPRII in Vascular Disease$423,750
R01 · FY2018 · HL · contact PI
Combination Gene Therapy in Combating Pulmonary Arterial Hypertension$98,446
R01 · FY2018 · HL · contact PI
Interactions of SERCA2a and BMPRII in Vascular Disease$423,750
R01 · FY2017 · HL · contact PI
Interactions of SERCA2a and BMPRII in Vascular Disease$423,750
R01 · FY2016 · HL · contact PI
Protein Phosphatase Inhibitor-1 and vascular smooth muscle cell function$134,865
K01 · FY2014 · HL · contact PI
Protein Phosphatase Inhibitor-1 and vascular smooth muscle cell function$134,865
K01 · FY2013 · HL · contact PI
Protein Phosphatase Inhibitor-1 and vascular smooth muscle cell function$134,865
K01 · FY2012 · HL · contact PI
Protein Phosphatase Inhibitor-1 and vascular smooth muscle cell function$134,865
K01 · FY2011 · HL · contact PI
Protein Phosphatase Inhibitor-1 and vascular smooth muscle cell function$134,865
K01 · FY2010 · HL · contact PI